Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Marcello Di NisioNick Van EsMarc CarrierTzu-Fei WangDavid GarciaAnnelise SegersJeffrey WeitzHarry BullerGary RaskobPublished in: Journal of thrombosis and haemostasis : JTH (2019)
The rates of recurrent VTE or major bleeding are relatively low among patients with active cancer receiving extended anticoagulant therapy beyond 6 months. Extended treatment with oral edoxaban appears as effective and safe as subcutaneous dalteparin.